SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

CELZ Expands ADAPT Trial

Creative Medical Technology Holdings expands ADAPT trial under new FDA clearance and advances toward Phase 3 planning for Olastrocel in chronic lower back pain

CELZ

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.